2023-2030 年胸导管的全球市场

市场概览

在预测期内 (2023-2030)，全球胸导管市场规模预计将以 6.2% 的复合年增长率增长。

胸导管是一种柔性管，通过胸部的切口（切口）插入胸部。 导管放置在胸膜腔内，并有许多孔以收集多余的液体。 胸腔导管被用作一线治疗，以提高患者的生活质量、患者安全、临床医生的效率、避免住院治疗，并以最少的干预有效缓解症状。

市场动态

当胸膜固定术失败或禁忌时，胸腔导管插入术作为恶性胸腔积液的一种治疗选择正变得越来越流行。 胸导管插入术被用作一线治疗，以提高患者的生活质量、安全性和临床医生的效率。 消除住院并以最少的干预实现有效的症状缓解是推动胸导管市场增长的关键因素。

全球心血管疾病患病率的上升预计将推动市场增长。

根据美国疾病控制和预防中心的数据，到 2020 年，心脏病将导致 382,□□776 名男性（四分之一的男性）和 314,186 名女性（五分之一的女性）死亡。 CVD是指一组心臟和血管疾病，包括冠状动脉疾病、脑血管疾病和风湿性心脏病。 超过五分之四的 CVD 死亡是由于心脏病发作和中风，其中三分之一在 70 岁之前过早死亡。

胸腔积液最常见的原因是充血性心力衰竭 (CHF)。 当胸膜微循环中增加的静水压力超过淋巴管重吸收多余液体的能力时，胸腔积液就会积聚在胸膜腔中。 大约 70% 的 CHF 患者会出现胸腔积液，但通常会在治疗基础疾病后重新吸收。 在有症状的患者中，在等待药物治疗反应时通常考虑进行治疗性胸腔穿刺术。 儘管进行了最佳的医疗管理，患者仍可能会反復出现有症状的胸腔积液。 因此，留置胸腔导管治疗充血性心力衰竭有效、耐受性好、并发症发生率低，可能是一种合理的治疗方法，尤其是对于非移植患者。 预计上述所有因素都将在预测期内推动市场。

与胸导管相关的并发症预计会阻碍市场增长。

胸腔导管常用于患有復发性心臟相关慢性疾病的患者。 虽然它可以很容易地插入而无需镇静，但它的使用与许多并发症有关。 导管相关性胸膜感染在患者中最常见。 与使用胸导管相关的其他风险包括导管导管转移、严重胸痛和导管脱位。 这些与胸导管长期存在于体内相关的并发症会给患者带来问题并阻碍市场增长。

COVID-19 影响分析

COVID-19 大流行给胸膜疾病管理带来了新的挑战。 由于资源和人员被转移到急性病 COVID-19 患者的管理上，胸膜疾病的常规医疗实践和服务提供受到严重干扰。 这也对胸膜癌和肺癌服务的提供造成了严重干扰，并且正在定期更新指南以反映这种流行病不断变化的情况。 例如，英国胸科学会 (BTS) 的 COVID-19 建议建议在确保患者和工作人员安全的同时减少医院就诊和住院治疗。提倡继续诊断途径。 此外，我们建议有症状的恶性胸腔积液患者接受治疗性大容量抽吸或一线留置胸腔导管 (IPC)，以避免需要住院进行胸腔引流或滑石粉胸膜固定术。我在这里。 应培训家庭尽可能排除 IPC，以减少与多次访问地区护士相关的风险。 根据当地的专业知识，适合化疗的癌症患者应接受日间护理胸腔镜检查或影像引导胸膜活检，有或没有 IPC。 因此，从上述因素来看，预计在预测期内市场将受到影响和改善。

内容

第1章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第4章市场动态

• 市场影响因素
  • 司机
    • 由于全球心血管疾病的增加，预计市场会增长。
  • 约束因素
    • 预计与胸导管相关的并发症会阻碍市场增长。
  • 机会
  • 影响分析

第5章行业分析

• 搬运工的五种力量
• 供应链
• 定价分析

第 6 章 COVID-19 分析

• COVID-19 市场分析
  • COVID-19 之前的市场情景
  • COVID-19 的当前市场情景
  • COVID-19 后或未来情景
• COVID-19 期间的价格动态
• 供需范围
• 大流行期间与市场相关的政府举措
• 製造商的战略举措
• 总结

第 7 章适应症

• 恶性胸腔积液
• 非恶性复发性胸腔积液
• 幽门胸膜炎
• 脑水肿
• 血胸

最终用户第 8 章

• 医院
• 门诊手术中心
• 其他

第9章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第10章竞争格局

• 竞争场景
• 市场情况/份额分析
• 併购分析

第11章公司简介

• 美敦力
  • 公司简介
  • 产品组合和说明
  • 主要亮点
  • 财务摘要
• Teleflex Incorporated
• Ply Gem Holdings Inc
• Smiths Group plc
• Medela AG
• ATMOS MedizinTechnik GmbH & Co. KG
• ARGON MEDICAL
• BD
• MAQUET Holding B.V. & Co. KG
• LivaNova PLC
• Cook Medical

第 12 章全球胸导管市场-DataM

Market Overview

The global pleural catheters market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 6.2% during the forecast period (2023-2030).

The pleural catheter is a flexible tube inserted through an incision (cut) in the chest and placed in the pleural cavity. The catheter sits in the pleural cavity and has many holes to collect the extra fluid. Pleural catheters are used as a first-line therapy to improve patient quality of life, patient safety, and clinician efficiency-freedom from hospitalization and effective symptomatic relief with minimal interventions.

Market Dynamics

Pleural catheters are becoming more popular worldwide as a treatment option for malignant pleural effusions when pleurodesis has failed or is contraindicated. Pleural catheters are used as first-line therapy to improve patient quality of life, safety, and clinician efficiency. Some critical factors driving the growth of the pleural catheter market include eliminating hospital admissions and providing effective symptomatic relief with minimal interventions.

The increasing prevalence of the cardiovascular disease worldwide is expected to drive market growth.

According to the Centers for Disease Control and Prevention, 2020, heart disease killed 382,776 men (1 in 4 male deaths) and 314,186 women (1 in 5 female deaths). CVDs are a group of heart and blood vessel disorders, including coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70.

The most common cause of the pleural effusion is congestive heart failure (CHF). When increased hydrostatic pressure in the pleural microcirculation exceeds the capacity of lymphatic vessels to reabsorb the excess fluid, fluid accumulates in the pleural space. Although pleural effusion occurs in approximately 70% of CHF patients, treatment of the underlying disease usually results in fluid reabsorption. In symptomatic patients, therapeutic thoracentesis is frequently considered while waiting for a pharmacological treatment effect. Patients may experience recurrent symptomatic pleural effusions despite optimal medical management. Therefore, indwelling pleural catheters are effective and well tolerated in congestive heart failure, have a low complication rate, and may be considered a reasonable treatment option, particularly for nontransplant candidates. Thus, from the above factors, the market is expected to drive in the forecast period..

Complications Associated with pleural catheters are expected to hamper the market growth.

Pleural catheters are commonly used in patients suffering from recurrent heart-related chronic diseases. Although they are simple to insert without sedation, many complications are associated with their use. Catheter-related pleural infections are the most common in patients. Other risks associated with using pleural catheters in patients include catheter tract metastases, severe chest pain, tube dislocation, etc. Such complications related to the long-term presence of pleural catheters in the body can cause problems for patients, hampering market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has created new challenges for pleural disease management. Routine medical practice and service provision for pleural diseases have been severely disrupted as resources and personnel have been redirected to manage acutely ill COVID-19 patients. This has also resulted in significant disruptions in the delivery of pleural and lung cancer services, with guidelines being updated regularly to reflect the ever-changing landscape of this pandemic. For instance, the British Thoracic Society (BTS) COVID-19 recommendations advocate for the continuation of diagnostic pathways for suspected cancer to reduce hospital visits and admissions while ensuring patient and staff safety. Moreover, patients with symptomatic malignant pleural effusions are advised to undergo either large-volume therapeutic aspirations or first-line indwelling pleural catheters (IPC), avoiding the need for hospitalization for chest drain and talc pleurodesis. Family members should be trained to drain IPCs whenever possible, reducing the risks posed by multiple district nurse visits. Depending on local expertise, patients with cancer who are candidates for anti-cancer therapy should have a day-case medical thoracoscopy with/without an IPC or image-guided pleural biopsies. Thus, from the above factors, the market got affected and is expected to improve in the forecast period.

Segment Analysis

Malignant Pleural Effusions segment is expected to hold the largest market share in pleural catheters

The malignant pleural effusions segment accounted for the largest market share in 2021. Many diseases can cause pleural effusion. It has been observed in infections, other diseases, and cancers. In general, fluid accumulates in the pleural space when there is an excess of fluid, a decrease in fluid absorption, or both. If the effusion is caused by cancer cells in the fluid, it is referred to as a "malignant pleural effusion" or MPE. When cells from lung cancer or another type of cancer spread to the pleural space, an MPE forms. These cancer cells increase pleural fluid production while decreasing fluid absorption.

Furthermore, people with lung cancer, breast cancer, and lymphoma (lymphatic tissue cancer) are more likely to get an MPE. Another common cause of MPE is mesothelioma (a rare cancer of the pleura). MPE can also be caused by cancer that has spread from the stomach, kidney, ovaries, or colon. Therefore, the increasing prevalence of cancer worldwide is expected to drive market growth in the forecast period. For instance, according to GLOBOCAN 2020, the number of new cancer cases diagnosed in 2020 is estimated to be 19.3 million, with nearly 10.0 million deaths due to cancer. GLOBOCAN predicts that cancer cases will reach 28.4 million by 2040. Female breast cancer has surpassed lung cancer as the most common cancer in the world (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%).

Additionally, in terms of cancer-related mortality, lung cancer is the leading cause, accounting for 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%). Men are more likely to develop lung, prostate, and colorectal cancers, whereas women are more likely to develop breast, colorectal, and lung cancers. The top ten cancers account for more than 60% of cancer incidence and 70% of cancer mortality. As a result, the demand for indwelling pleural catheters (IPC) has increased because this device is a small catheter placed under your skin and into the pleural fluid, allowing for repeated drainage at home (without any more needle sticks) to relieve symptoms. These catheters are placed as an outpatient procedure under local anesthesia. The catheter is safe and simple to use and may eventually allow the lung to expand fully up to the chest wall. After the fluid buildup subsides, many patients can have the catheter removed after 2-3 months. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global pleural catheters market

North America region accounted for the largest market share in 2021. The increasing prevalence of pleural diseases, rising cases of cardiovascular disease, cancer and infectious disease, increasing number of thoracic surgeries, increasing demand for minimally invasive processes and favorable reimbursement policies are the factors to drive the market in the forecast period. For instance, according to the National Center For Biotechnology Information Report 2022, pleural effusion is the most common pleural disease, affecting 1.5 million patients in the United States annually. Pleural effusions can be caused by a variety of conditions, including lung diseases such as pneumonia and asbestos exposure, systemic diseases such as lupus and rheumatoid arthritis, or the pleural manifestation of diseases that affect other organs such as congestive heart failure, pancreatitis, or conditions local to the pleura such as pleural infections and mesothelioma. Therefore, it has increased the demand for pleural catheters. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the pleural catheters market are Medtronic, Teleflex Incorporated, Ply Gem Holdings Inc, Smiths Group plc, Medela AG, ATMOS MedizinTechnik GmbH & Co. KG, ARGON MEDICAL, BD, MAQUET Holding B.V. & Co. KG, LivaNova PLC and Cook Medical.

Teleflex Incorporated:

Overview:

Teleflex Incorporated is an American provider of specialty medical devices for various critical care and surgical procedures. The firm reports seven segments: vascular access, interventional, surgical, anesthesia, interventional urology, original-equipment manufacturing, and all others. Teleflex is the home of Arrow, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift and Weck - trusted brands united by a common sense of purpose. The company's geographic exposure is predominantly in the United States, accounting for 60% of revenue, with overseas markets accounting for the remaining 40%.

Product Portfolio:

Arrow-Clarke Thoracentesis Device: The Arrow-Clarke Thoracentesis Device permits the removal of fluids from the pleural space and provides access to infuse chemotherapeutic or sclerosing agents.

The global pleural catheters market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The increasing prevalence of the cardiovascular disease worldwide is expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. Complications Associated with pleural catheters are expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces
• 5.2. Supply Chain
• 5.3. Pricing Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Indication

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
  • 7.1.2. Market Attractiveness Index, By Indication
• 7.2. Malignant Pleural Effusions*
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Non-Malignant Recurrent Effusions
• 7.4. Chylothorax
• 7.5. Empyema
• 7.6. Haemothorax

8. By End user

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 8.1.2. Market Attractiveness Index, By End user
• 8.2. Hospitals*
  • 8.2.1.1. Introduction
  • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Ambulatory Surgical Center
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Medtronic*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Teleflex Incorporated
• 11.3. Ply Gem Holdings Inc
• 11.4. Smiths Group plc
• 11.5. Medela AG
• 11.6. ATMOS MedizinTechnik GmbH & Co. KG
• 11.7. ARGON MEDICAL
• 11.8. BD
• 11.9. MAQUET Holding B.V. & Co. KG
• 11.10. LivaNova PLC
• 11.11. Cook Medical

LIST NOT EXHAUSTIVE

12. Global Pleural Catheters Market- DataM

• 12.1. Appendix
• 12.2. About Us and Applications
• 12.3. Contact Us